Abstract
RUNX3, a Runt domain transcription factor involved in TGF-β signaling, is a candidate tumor-suppressor gene localized in 1p36, a region commonly deleted in a wide variety of human tumors, including those of the stomach, bile duct, and pancreas. Recently, frequent inactivation of RUNX3 has been demonstrated in human gastric carcinomas. In this study, to examine the involvement of RUNX3 abnormalities in tumorigenesis of bile duct as well as pancreatic cancers, we investigated not only the expression but also methylation status of RUNX3 in 10 human bile duct and 12 pancreatic cancer cell lines. Seven (70%) of the bile duct and nine (75%) of the pancreatic cancer cell lines exhibited no expression of RUNX3 by both Northern blot analysis and the reverse transcriptase polymerase chain reaction. All of the 16 cell lines that did not express RUNX3 also showed methylation of the promoter CpG island of the gene, whereas the six cell lines that showed RUNX3 expression were not methylated or only partially methylated in the RUNX3 promoter region. Moreover, treatment with the methylation inhibitor 5′-aza-2′-deoxycitidine activated RUNX3 mRNA expression in all of 16 cancer cell lines that originally lacked RUNX3 expression. Finally, hemizygous deletion of RUNX3, as detected by fluorescence in situ hybridization, was found in 15 of the 16 cancer cell lines that lacked RUNX3 expression. These data suggest that the inactivation of RUNX3 plays an important role in bile duct and pancreatic carcinogenesis, and that methylation is a common mechanism by which the gene is inactivated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M and Ito Y . (1995). Gene, 159, 245–248.
Baylin SB and Herman JG . (2000). Trends Genet., 16, 168–174.
Bisgaard HC and Thorgeirsson SS . (1991). J. Cell. Physiol., 147, 333–343.
Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP and Bouck N . (1998). Cell, 93, 1159–1170.
Daga A, Karlovich CA, Dumstrei K and Banerjee U . (1996). Genes Dev., 10, 1194–1205.
Eng C, Herman JG and Baylin SB . (2000). Nat. Genet., 24, 101–102.
Goggins M, Kern SE, Offerhaus JA and Hruban RH . (1999). Ann. Oncol., 4 (Suppl 10), 4–8.
Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K and Ito Y . (1999). J. Biol. Chem., 274, 31577–31582.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (2000). Mod. Pathol., 13, 627–631.
Ishino S, Hashimoto N, Fushiki S, Date K, Mori T, Fujimoto M, Nakagawa Y, Ueda S, Abe T and Inazawa J . (1998). Cancer, 83, 360–366.
Ito Y . (1999). Genes Cells, 12, 685–696.
Kang YK, Kim YI and Kim WH . (2000). Mod. Pathol., 13, 627–631.
Kania MA, Bonner AS, Duffy JB and Gergen JP . (1990). Genes Dev., 10, 1701–1713.
Lee S, Kim WH, Jung HY, Yang MH and Kang GH . (2002). Am. J. Pathol., 161, 1015–1022.
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y . (2002). Cell, 109, 113–124.
Logsdon CD, Keyes L and Beauchamp RD . (1992). Am. J. Physiol., 262, G364–G368.
Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW and Vogelstein B . (1995). Cancer Res., 55, 5548–5550.
Schleger C, Arens N, Zentgraf H, Bleyl U and Verbeke C . (2000). J. Pathol., 191, 27–32.
Schnall SF and Macdonald JS . (1996). Semin. Oncol., 23, 220–228.
Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE and Herman JG . (1997). Cancer Res., 57, 3126–3130.
Takenoshita S, Tani M, Miyoshi H, Matsui M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC and Yokota J . (1998). Carcinogenesis, 19, 803–807.
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH and Goggins M . (2000). Cancer Res., 60, 1835–1839.
Weith A, Brodeur GM, Bruns GA, Matise TC, Mischke D, Nizetic D, Seldin MF, van Roy N and Vance J . (1996). Cytogenet. Cell Genet., 72, 114–144.
Yazumi S, Ko K, Watanabe N, Shinohara H, Yoshikawa K, Chiba T and Takhashi R . (2000). Int. J. Cancer, 86, 782–789.
Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M and Uchida K . (1995). Cancer Res., 55, 2756–2760.
Acknowledgements
We thank Ms Pamela Paradis Tice, ELS (D), for editing the manuscript. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Culture and Science of Japan (11470130, 11877090, 11670496, and 13670510).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wada, M., Yazumi, S., Takaishi, S. et al. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines. Oncogene 23, 2401–2407 (2004). https://doi.org/10.1038/sj.onc.1207395
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207395
Keywords
This article is cited by
-
Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India
Cancer Cell International (2020)
-
DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition
Cancer Cell International (2018)
-
LINE-1 methylation level and prognosis in pancreas cancer: pyrosequencing technology and literature review
Surgery Today (2017)
-
The RUNX family in breast cancer: relationships with estrogen signaling
Oncogene (2013)
-
Is RUNX3 a new player in the pathogenesis of ankylosing spondylitis?
Rheumatology International (2013)